Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Summary: Background: Despite considerable advances over the last two decades in the molecular understanding of cholestasis and cholestatic liver disease, little improvement has been made in diagnostic tools and therapeutic strategies. Aims: To critically review controversial aspects of the scientific basis for common clinical practice in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and to discuss key ongoing challenges to improve patient management. Methods: We performed a literature search using PubMed and by examining the reference lists of relevant review articles related to the clinical management of PBC and PSC. Articles were considered on the background of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) practice guidelines and clinical experience of the authors. Results: Ongoing challenges in PBC mainly pertain to the improvement of medical therapy, particularly for patients with a suboptimal response to ursodeoxycholic acid. In PSC, development of medical therapies and sensitive screening protocols for cholangiocarcinoma represent areas of intense research. To rationally improve patient management, a better understanding of pathogenesis, including complications like pruritis and fatigue, is needed and there is a need to identify biomarker end‐points for treatment effect and prognosis. Timing of liver transplantation and determining optimal regimens of immunosuppression post‐liver transplantation will also benefit from better appreciation of pre‐transplant disease mechanisms. Conclusion: Controversies in the management of PBC and PSC relate to topics where evidence for current practice is weak and further research is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Host-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
Duboc, H., Rajca, S., Rainteau, D., Benarous, D., Maubert, M.-A., Quervain, E., Thomas, G., Barbu, V., Humbert, L., Despras, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302578 · Cited by 930
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments
Swann, J. R., Want, E. J., Geier, F. M., Spagou, K., Wilson, I. D., Sidaway, J. E., Nicholson, J. K., & Holmes, E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006734107 · Cited by 726
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725 · cited 21×
“There is also a relationship between acute cellular rejection (against which corticosteroids would protect) and PSC recurrence.152 The topic is of considerable interest as long-term follow-up indicates that PSC recurrence does increase re-transplantation rates.153 Interpreting the relationship between disease recurren…”
BackgroundInfluentialBiochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 2×
“Lindberg et al.(37) 1997–2001 Stockholm,”
InfluentialSoetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555 · cited 1×
“deals thoroughly with the controversy as to whether ‘overlap syndrome’ (Figure 2) should be considered a separate disease entity.(157) If the patients fulfil a diagnosis of PBC or PSC, this should, according to this consensus document, be the primary diagnosis and co-occurring”
BackgroundSelf-citationDrug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417 · cited 1×
“et al.(40) 1995–2004 Seattle, WA, US 51 (37 with”
Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.009 · Cited by 410
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis
Liu, X., Invernizzi, P., Lu, Y., Kosoy, R., Lu, Y., Bianchi, I., Podda, M., Xu, C., Xie, G., Macciardi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.627 · Cited by 398
Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22441 · Cited by 393
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
Beuers, U., Hohenester, S., de Buy Wenniger, L. J. M., Kremer, A. E., Jansen, P. L. M., & Elferink, R. P. J. O. (2010) · Hepatology · doi:10.1002/hep.23810 · Cited by 351
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315
The immunobiology and pathophysiology of primary biliary cirrhosis
Hirschfield, G. M., & Gershwin, M. E. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164014 · Cited by 315
Guo, G. L., Lambert, G., Negishi, M., Ward, J. M., Brewer, H. B., Kliewer, S. A., Gonzalez, F. J., & Sinal, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307145200 · Cited by 312
The natural history of small-duct primary sclerosing cholangitis
Björnsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R. W., Boberg, K. M., & Angulo, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.042 · Cited by 305
Self-citationAlabraba, E., Nightingale, P., Gunson, B., Hubscher, S., Olliff, S., Mirza, D., & Neuberger, J. (2009) · Liver Transplantation · doi:10.1002/lt.21679 · Cited by 298
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287 · cited 3×
“Hypotheses range from endotoxin leakage,85 via pathogenic changes to the gut microbiota,86 to aberrant homing of intestinally activated lymphocytes to engage in biliary 286 Aliment Pharmacol Ther 2014; 39: 282-301 ª 2013 John Wiley & Sons Ltd Study Year Treatment N (treat/ control) Study duration Lab Histology OLT-fre…”
BackgroundInfluentialNakamura, M., Nishida, N., Kawashima, M., Aiba, Y., Tanaka, A., Yasunami, M., Nakamura, H., Komori, A., Nakamuta, M., Zeniya, M., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.08.010 · Cited by 267 · cited 5×
“References for studies refer to the online supplementary reference list (Data S1 for tables 1–5) Study Year Dose (mg/kg bw/ day) N (treat/ control) Study duration Lab Histology CCA OLT-free survival Outcome O’Brien et al.49 1991 10 12* 2.5 years + ND ND ND Improvement of liver tests in treatment periods and worsening…”
InfluentialTreatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Impact of fatigue on the quality of life of patients with primary biliary cirrhosis
Huet, P.-M., Deslauriers, J., Tran, A., Faucher, C., & Charbonneau, J. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01857.x · Cited by 262
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70351-3 · Cited by 247
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242
Fatigue in primary biliary cirrhosis
Cauch-Dudek, K., Abbey, S., Stewart, D. E., & Heathcote, E. J. (1998) · Gut · doi:10.1136/gut.43.5.705 · Cited by 237
Effects of long-term rifampicin administration in primary biliary cirrhosis
Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90335-v · Cited by 235
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228
Impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study
Mells, G. F., Pells, G., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Hepatology · doi:10.1002/hep.26365 · Cited by 227
Pruritus in cholestasis: facts and fiction
Beuers, U., Kremer, A. E., Bolier, R., & Elferink, R. P. J. O. (2014) · Hepatology · doi:10.1002/hep.26909 · Cited by 225
Rautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., Pikkarainen, P., Nuutinen, H., & Färkkilä, M. (2005) · Hepatology · doi:10.1002/hep.20646 · Cited by 222
Angulo, P., Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M., Kamath, P. S., & Dickson, E. R. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00020.x · Cited by 203 · cited 2×
“Comment Ponsioen et al.35 1987–1996 Amsterdam, The Netherlands 43 47 No abnormalities Reactive changes Some atypia Suspicious Adenocarcinoma Cytology Suspicious or adenoca 60 89 Siqueira et al.36 1984–1987 Pittsburgh, PA, US 151 318 Negative Suspicious Highly atypical Positive Cytology Positive 46.4 100 Lindberg et al…”
InfluentialThe true impact of fatigue in primary biliary cirrhosis: A population study
Goldblatt, J., Taylor, P. J. S., Lipman, T., Prince, M. I., Baragiotta, A., Bassendine, M. F., James, O. F. W., & Jones, D. E. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32993 · Cited by 202
Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis
Kaya, M., Petersen, B. T., Angulo, P., Baron, T. H., Andrews, J. C., Gostout, C. J., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03690.x · Cited by 196 · cited 1×
“Both strategies are in current practice, 142 yet the additional value of stenting is not established and has been claimed to associate with increased frequencies of cholangitis.(143) As to either approach, the threshold”
BackgroundQuality of life before and after liver transplantation for cholestatic liver disease
Gross, C. R., Malinchoc, M., Kim, R. W., Evans, R. W., Wiesner, R. H., Petz, J. L., Crippin, J. S., Klintmalm, G. B., Levy, M. F., Ricci, P., et al. (1999) · Hepatology · doi:10.1002/hep.510290229 · Cited by 192
Amano, K., Leung, P. S. C., Rieger, R., Quan, C., Wang, X., Marik, J., Suen, Y. F., Kurth, M. J., Nantz, M. H., Ansari, A. A., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5874 · Cited by 187
Charatcharoenwitthaya, P., Pimentel, S., Talwalkar, J. A., Enders, F. T., Lindor, K. D., Krom, R. A. F., & Wiesner, R. H. (2007) · Liver Transplantation · doi:10.1002/lt.21124 · Cited by 179
Recurrence and rejection in liver transplantation for primary sclerosing cholangitis
Fosby, B. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i1.1 · Cited by 175 · cited 1×
“There is also a relationship between acute cellular rejection (against which corticosteroids would protect) and PSC recurrence.(152) The topic is of considerable interest as long-term follow-up indicates that PSC recurrence does increase re-transplantation rates.”
BackgroundLundqvist, K., & Broomé, U. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02258391 · Cited by 159
Ruiz, A., Lemoinne, S., Carrat, F., Corpechot, C., Chazouillères, O., & Arrivé, L. (2014) · Hepatology · doi:10.1002/hep.26620 · Cited by 144
Cullen, S. N., Rust, C., Fleming, K., Edwards, C., Beuers, U., & Chapman, R. W. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.023 · Cited by 136
Liu, H., Norman, G. L., Shums, Z., Worman, H. J., Krawitt, E. L., Bizzaro, N., Vergani, D., Bogdanos, D. P., Dalekos, G. N., Milkiewicz, P., et al. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2010.09.005 · Cited by 130
Lewis, J. T., Talwalkar, J. A., Rosen, C. B., Smyrk, T. C., & Abraham, S. C. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181bc96f9 · Cited by 122
Lens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International · doi:10.1111/liv.12290 · Cited by 107 · cited 3×
“Comment Ponsioen et al.35 1987–1996 Amsterdam, The Netherlands 43 47 No abnormalities Reactive changes Some atypia Suspicious Adenocarcinoma Cytology Suspicious or adenoca 60 89 Siqueira et al.36 1984–1987 Pittsburgh, PA, US 151 318 Negative Suspicious Highly atypical Positive Cytology Positive 46.4 100 Lindberg et al…”
BackgroundInfluentialWannhoff, A., Hov, J. R., Folseraas, T., Rupp, C., Friedrich, K., Anmarkrud, J. A., Weiss, K. H., Sauer, P., Schirmacher, P., Boberg, K. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.005 · Cited by 94
Self-citationJones, D. E., Al-Rifai, A., Frith, J., Patanwala, I., & Newton, J. L. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.026 · Cited by 91
Recurrent primary biliary cirrhosis after liver transplantation
Silveira, M. G., Talwalkar, J. A., Lindor, K. D., & Wiesner, R. H. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03038.x · Cited by 86
Bizzaro, N., Covini, G., Rosina, F., Muratori, P., Tonutti, E., Villalta, D., Pesente, F., Alessio, M. G., Tampoia, M., Antico, A., et al. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8234-y · Cited by 79
Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis
MOAYYERI, A., DARYANI, N. E., BAHRAMI, H., HAGHPANAH, B., NAYYER‐HABIBI, A., & SADATSAFAVI, M. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03727.x · Cited by 60
Jin, Q., Moritoki, Y., Lleo, A., Tsuneyama, K., Invernizzi, P., Moritoki, H., Kikuchi, K., Lian, Z.-X., Hirschfield, G. M., Ansari, A. A., et al. (2012) · Hepatology · doi:10.1002/hep.25511 · Cited by 37
Cited by
(2015) · Diagnostic Imaging: Gastrointestinal · doi:10.1016/b978-0-323-37755-3.50202-6 · Cited by 811
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.009 · Cited by 297
Aabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy · doi:10.1055/s-0043-107029 · Cited by 255
Self-citationGenetics of primary sclerosing cholangitis and pathophysiological implications
Jiang, X., & Karlsen, T. H. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.154 · Cited by 155
Self-citationCheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
Metadata
- Authors
- Karlsen, T. H., Vesterhus, M., & Boberg, K. M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-12-29
- Volume
- 39
- Issue
- 3
- Pages
- 282-301
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2121484013
- Cited by
- 86
- References
- 58
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.